Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: A population-based study in Shanghai, China

Carcinogenesis

Volumn 27, Issue 6, 2006, Pages 1251-1256

  Sakoda, Lori C ^a   Gao, Yu Tang ^b   Chen, Bingshu E ^a   Chen, Jinbo ^a   Rosenberg, Philip S ^a   Rashid, Asif ^c   Deng, Jie ^b   Shen, Ming Chang ^d   Wang, Bing Sheng ^d   Han, Tian Quan ^e   Zhang, Bai He ^f   Cohen Webb, Hope ^g   Yeager, Meredith ^a   Welch, Robert ^a   Chanock, Stephen ^a   Fraumeni Jr , Joseph F ^a   Hsing, Ann W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SHANGHAI CANCER INSTITUTE   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d FUDAN UNIVERSITY   (China)

^e SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g WESTAT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ALLELE; ARTICLE; BILIARY TRACT CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER TISSUE; CASE CONTROL STUDY; CHINA; CHRONIC INFLAMMATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG USE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; GALLSTONE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; RISK REDUCTION;

EID: 33745630328     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi314     Document Type: Article

References (32)

1. Hsing,A.W., Rashid,A., Devesa,S.S. and Fraumeni,J.F. Jr (2006) Biliary tract cancer. In Schottenfeld,D. and Fraumeni,J.F. Jr (eds) Cancer Epidemiology and Prevention. 3rd ed. Oxford University Press, NY (in press).
2. Wistuba,I.I. and Gazdar,A.F. (2004) Gallbladder cancer: Lessons from a rare tumour. Nat. Rev. Cancer, 4, 695-706.
3. Coogan,P.F., Rosenberg,L., Palmer,J.R., Strom,B.L., Zauber,A.G., Stolley,P.D. and Shapiro,S. (2000) Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol. Biomarkers Prev., 9, 119-123.
4. Gonzalez-Perez,A., Garcia Rodriguez,L.A. and Lopez-Ridaura,R. (2003) Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: A meta-analysis. BMC Cancer, 3, 28.
5. Hsing,A.W., Gao,Y.T., Devesa,S.S., Jin,F. and Fraumeni,J.F. Jr (1998) Rising incidence of biliary tract cancers in Shanghai, China. Int. J. Cancer, 75, 368-370.
6. Liu,E., Sakoda,L.C., Gao,Y. et al. (2005) Aspirin use and risk of biliary tract cancer: A population-based study in Shanghai, China. Cancer Epidemiol. Biomarkers Prev., 14, 1315-1318.
7. Zha,S., Yegnasubramanian,V., Nelson,W.G., Isaacs,W.B. and De Marzo,A.M. (2004) Cyclooxygenases in cancer: Progress and perspective. Cancer Lett., 215, 1-20.
8. Ghosh,M., Kawamoto,T., Koike,N. et al. (2000) Cyclooxygenase expression in the gallbladder. Int. J. Mol. Med., 6, 527-532.
9. Asano,T., Shoda,J., Ueda,T. et al. (2002) Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: Crucial role of arachidonate metabolism in tumor growth and progression. Clin. Cancer Res., 8, 1157-1167.
10. Kawamoto,T., Shoda,J., Asano,T., Ueda,T., Furukawa,M., Koike,N., Tanaka,N., Todoroki,T. and Miwa,M. (2002) Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int. J. Cancer, 98, 427-434.
11. Hayashi,N., Yamamoto,H., Hiraoka,N. et al. (2001) Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm. Hepatology, 34, 638-650.
12. Shacter,E. and Weitzman,S.A. (2002) Chronic inflammation and cancer. Oncology (Huntingt), 16, 217-226, 229.
13. Kosaka,T., Miyata,A., Ihara,H., Hara,S., Sugimoto,T., Takeda,O., Takahashi,E. and Tanabe,T. (1994) Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur. J. Biochem., 221, 889-897.
14. Cox,D.G., Pontes,C., Guino,E., Navarro,M., Osorio,A., Canzian,F. and Moreno,V. (2004) Polymorphisms in prostaglandin synthase 2/ cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br. J. Cancer, 91, 339-343.
15. Koh,W.P., Yuan,J.M., van den Berg,D., Lee,H.P. and Yu,M.C. (2004) Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: The Singapore Chinese Health Study. Br. J. Cancer, 90, 1760-1764.
16. Campa,D., Zienolddiny,S., Maggini,V., Skaug,V., Haugen,A. and Canzian,F. (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis, 25, 229-235.
17. Hu,Z., Miao,X., Ma,H., Wang,X., Tan,W., Wei,Q., Lin,D. and Shen,H. (2005) A common polymorphism in the 3′ UTR of cyclooxygenase 2/ prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer, 48, 11-17.
18. Sorensen,M., Autrup,H., Tjonneland,A., Overvad,K. and Raaschou-Nielsen,O. (2005) A genetic polymorphism in prostaglandin synthase 2 (8473, T→C) and the risk of lung cancer. Cancer Lett., 226, 49-54.
19. Panguluri,R.C., Long,L.O., Chen,W. et al. (2004) COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis, 25, 961-966.
20. Kang,S., Kim,Y.B., Kim,M.H. et al. (2005) Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett., 217, 11-16.
21. Packer,B.R., Yeager,M., Staats,B. et al. (2004) SNP500Cancer: A public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res., 32, D528-D532.
22. Armitage,P. (1955) Tests for linear trends in proportions and frequencies. Biometrics, 11, 375-386.
23. Simes,R.J. (1986) An improved Bonferroni procedure for multiple tests of significance. Biometrika, 73, 751-754.
24. Rosenberg,P.S., Che,A. and Chen,B.E. (2006) Multiple hypothesis testing strategies for genetic case-control association studies. Statist. Med., (in press).
25. Barrett,J.C., Fry,B., Maller,J. and Daly,M.J. (2005) Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
26. Schaid,D.J., Rowland,C.M., Tines,D.E., Jacobson,R.M. and Poland,G.A. (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am. J. Hum. Genet., 70, 425-434.
27. Excoffier,L. and Slatkin,M. (1995) Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol. Biol. Evol., 12, 921-927.
28. MacFaul,G.R. and Chapman,R.W. (2004) Sclerosing cholangitis. Curr. Opin. Gastroenterol., 20, 275-280.
29. Dixon,D.A., Kaplan,C.D., McIntyre,T.M., Zimmerman,G.A. and Prescott,S.M. (2000) Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J. Biol. Chem., 275, 11750-11757.
30. Campa,D., Hung,R.J., Mates,D. et al. (2005) Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol. Biomarkers Prev., 14, 538-539.
31. Fritsche,E., Baek,S.J., King,L.M., Zeldin,D.C., Eling,T.E. and Bell,D.A. (2001) Functional characterization of cyclooxygenase-2 polymorphisms. J. Pharmacol. Exp. Ther., 299, 468-476.
32. Goodman,J.E., Bowman,E.D., Chanock,S.J., Alberg,A.J. and Harris,C.C. (2004) Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis, 25, 2467-2472.